Cibc World Market Inc. Has $4.88 Million Holdings in West Pharmaceutical Services, Inc. $WST

Cibc World Market Inc. grew its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 300.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,586 shares of the medical instruments supplier’s stock after buying an additional 13,940 shares during the quarter. Cibc World Market Inc.’s holdings in West Pharmaceutical Services were worth $4,876,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of WST. Generation Investment Management LLP bought a new stake in West Pharmaceutical Services during the 2nd quarter worth approximately $255,072,000. Norges Bank acquired a new position in West Pharmaceutical Services in the second quarter worth $200,813,000. ProShare Advisors LLC grew its holdings in shares of West Pharmaceutical Services by 46.8% during the second quarter. ProShare Advisors LLC now owns 738,368 shares of the medical instruments supplier’s stock worth $161,555,000 after purchasing an additional 235,272 shares during the last quarter. Amundi increased its stake in shares of West Pharmaceutical Services by 83.4% in the second quarter. Amundi now owns 502,831 shares of the medical instruments supplier’s stock valued at $111,236,000 after buying an additional 228,696 shares in the last quarter. Finally, Border to Coast Pensions Partnership Ltd bought a new position in shares of West Pharmaceutical Services in the third quarter valued at about $40,853,000. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Up 2.6%

Shares of NYSE:WST opened at $249.99 on Friday. The company has a 50 day moving average price of $260.95 and a two-hundred day moving average price of $261.61. The company has a market capitalization of $17.98 billion, a PE ratio of 36.82, a PEG ratio of 3.31 and a beta of 1.18. West Pharmaceutical Services, Inc. has a 52 week low of $187.43 and a 52 week high of $322.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.18 and a current ratio of 3.02.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, February 12th. The medical instruments supplier reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.21. The business had revenue of $805.00 million during the quarter, compared to analysts’ expectations of $795.70 million. West Pharmaceutical Services had a net margin of 16.06% and a return on equity of 17.90%. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.82 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. Analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 4th. Stockholders of record on Wednesday, January 28th were issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date was Wednesday, January 28th. West Pharmaceutical Services’s payout ratio is 13.04%.

Trending Headlines about West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Beat-and-guide: WST reported Q4 EPS of $2.04 vs. $1.83 consensus and revenue of $805M, and issued FY‑2026 EPS guidance of $7.85–$8.20 with revenue ~$3.2–3.3B — the core reason investors pushed the stock higher. West Reports Fourth-Quarter and Full-Year 2025 Results
• Positive Sentiment: Strong demand for drug components: Reuters highlights management’s forecast for 2026 profit above estimates driven by robust demand for HVP components (syringes, cartridges), supporting margin and cash‑flow outlook. West Pharma forecasts 2026 profit above estimates on strong demand for drug components
• Positive Sentiment: Proprietary product progress and outlook: Company commentary and analyst notes emphasize SmartDose and HVP-led growth, with management signaling SmartDose sale activity by mid‑2026 — a potential revenue/margin driver. WST’s Q4 Earnings & Sales Beat, SmartDose Sale by Mid-2026, Stock Up
• Positive Sentiment: Analyst support: TD Cowen reiterated a Buy and kept a $350 price target, citing non‑GLP‑1 growth, margin expansion and regulatory tailwinds — reinforcing investor confidence. Buy Rating on West
• Positive Sentiment: Market reaction coverage: Multiple outlets (Yahoo, Seeking Alpha, TipRanks) note stock strength following results and outlook, reflecting broad positive market reception. West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook
• Neutral Sentiment: Guidance detail and call transcript: The full earnings call transcript and slide deck provide execution details and cadence for HVP and SmartDose commercialization — useful for modeling but not new directional news. West Pharmaceutical Services Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Peer/value comparison: A Zacks piece compares Cooper (COO) and WST for value seekers — useful for allocation decisions but not directly driving WST’s move. COO vs. WST: Which Stock Is the Better Value Option?
• Neutral Sentiment: Macro market commentary: Coverage noting WST’s role in broader indices/futures is descriptive — relevant for positioning but secondary to fundamentals. Is West Pharmaceutical Services (NYSE:WST) a Pillar In S&P 500 Futures Performance
• Negative Sentiment: Relative underperformance note: MarketWatch flags that WST has underperformed some competitors recently despite daily gains — a reminder of sector competition and potential valuation scrutiny. West Pharmaceutical Services Inc. stock underperforms despite daily gains

Wall Street Analyst Weigh In

WST has been the topic of a number of research analyst reports. KeyCorp increased their price objective on shares of West Pharmaceutical Services from $325.00 to $350.00 and gave the stock an “overweight” rating in a report on Friday, October 24th. Jefferies Financial Group reiterated a “buy” rating and set a $295.00 target price on shares of West Pharmaceutical Services in a research report on Tuesday. Morgan Stanley initiated coverage on shares of West Pharmaceutical Services in a report on Monday, December 1st. They issued an “equal weight” rating and a $285.00 price target for the company. Barclays dropped their price objective on shares of West Pharmaceutical Services from $325.00 to $265.00 and set an “equal weight” rating for the company in a research report on Friday. Finally, Evercore decreased their price objective on West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 3rd. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, West Pharmaceutical Services presently has a consensus rating of “Buy” and an average target price of $314.56.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.